Becton recently reported first quarter fiscal 2010 results. Earnings per share of $1.30 easily beats the Zacks Consensus Estimate of $1.20 and the year-ago earnings of $1.26. The company also reported an expansion in its top-line with growth across all major business segments.
BD Medical revenues increased 16% year over year to $1.019 billion. Growth can be attributed to higher sales of Medical Surgical, Pharmaceutical Systems and Diabetes Care products.
BD Diagnostics revenues increased 10% year over year to $595 million. Growth was primarily due to higher demand for the company’s safety-engineered devices and infectious disease testing systems.
BD Biosciences revenues were approximately flat year over year at $303 million. Becton’s capital funding constraints negatively impacted sales of clinical and research instruments in this business category.
Becton has also raised its sales and earnings per share guidance for full fiscal 2010. For the year, Becton now expects revenues to increase roughly 7% year over year, compared to the previous guidance of 6%. Earnings per share should increase approximately 2%−4% year over year to $5.05−$5.15. Becton’s previous guidance was an increase of 1%−3% year over year in earnings per share.
Becton, Dickinson and Company develops, manufactures and markets medical devices, supplies, laboratory equipment and diagnostic products globally. The company is a world leader in safety needle products. Becton competes with players like Baxter International Inc. , Johnson & Johnson and Abbott Laboratories
Work From Home
Learn from world's #1 internet wealth advocate for making money on line, Stephen Pierce.
BD Medical revenues increased 16% year over year to $1.019 billion. Growth can be attributed to higher sales of Medical Surgical, Pharmaceutical Systems and Diabetes Care products.
BD Diagnostics revenues increased 10% year over year to $595 million. Growth was primarily due to higher demand for the company’s safety-engineered devices and infectious disease testing systems.
BD Biosciences revenues were approximately flat year over year at $303 million. Becton’s capital funding constraints negatively impacted sales of clinical and research instruments in this business category.
Becton has also raised its sales and earnings per share guidance for full fiscal 2010. For the year, Becton now expects revenues to increase roughly 7% year over year, compared to the previous guidance of 6%. Earnings per share should increase approximately 2%−4% year over year to $5.05−$5.15. Becton’s previous guidance was an increase of 1%−3% year over year in earnings per share.
Becton, Dickinson and Company develops, manufactures and markets medical devices, supplies, laboratory equipment and diagnostic products globally. The company is a world leader in safety needle products. Becton competes with players like Baxter International Inc. , Johnson & Johnson and Abbott Laboratories
Work From Home
Learn from world's #1 internet wealth advocate for making money on line, Stephen Pierce.
Posts
No comments:
Post a Comment